Regulation of Motivation to Self-administer Ethanol by MGluR5 in Alcohol-preferring (P) Rats
Overview
Affiliations
Background: Emerging evidence indicates that Group I metabotropic glutamate receptors (mGluR1 and mGluR5) differentially regulates ethanol self-administration in several rodent behavioral models. The purpose of this work was to further characterize involvement of Group I mGluRs in the reinforcing effects of ethanol using a progressive ratio schedule of reinforcement.
Methods: Alcohol-preferring (P) rats were trained to self-administer ethanol (15% v/v) versus water on a concurrent schedule of reinforcement, and the effects of the Group I mGluR antagonists were evaluated on progressive ratio performance. The rats were then trained to self-administer sucrose (0.4% w/v) versus water, and the effects of the antagonists were tested on progressive ratio performance.
Results: The mGluR1 antagonist, 3,4-dihydro-2H-pyrano[2,3]b quinolin-7-yl (cis-4-methoxycyclohexyl) methanone (JNJ 16259685; 0 to 1 mg/kg) and the mGluR5 antagonist, 6-methyl-2-(phenylethynyl) pyridine (MPEP; 0 to 10 mg/kg) dose-dependently reduced ethanol break point. In separate locomotor activity assessments, the lowest effective dose of JNJ 16259685 (0.3 mg/kg) produced a motor impairment, whereas the lowest effective dose of MPEP (3 mg/kg) did not. Thus, the reduction in ethanol break point by mGluR1 antagonism was probably a result of a motor impairment. JNJ 16259685 (0.3 mg/kg) and MPEP (10 mg/kg) reduced sucrose break point and produced motor impairments. Thus, the reductions in sucrose break point produced by both Group I antagonists were probably because of nonspecific effects on motor activity.
Conclusions: Together, these results suggest that glutamate activity at mGluR5 regulates motivation to self-administer ethanol.
Faccidomo S, Eastman V, Santanam T, Swaim K, Taylor S, Hodge C Front Behav Neurosci. 2025; 18:1498201.
PMID: 39911242 PMC: 11794300. DOI: 10.3389/fnbeh.2024.1498201.
Leyrer-Jackson J, Kufahl P, Olive M Pharmacol Biochem Behav. 2025; 248:173958.
PMID: 39805474 PMC: 11846690. DOI: 10.1016/j.pbb.2025.173958.
Newton K, De Biase L Adv Neurobiol. 2024; 37:343-355.
PMID: 39207701 DOI: 10.1007/978-3-031-55529-9_19.
Fabian C, Jordan N, Cole R, Carley L, Thompson S, Seney M Neuropsychopharmacology. 2024; 49(12):1861-1871.
PMID: 38773314 PMC: 11473522. DOI: 10.1038/s41386-024-01889-0.
Tap S Addict Biol. 2024; 29(4):e13386.
PMID: 38600715 PMC: 11007263. DOI: 10.1111/adb.13386.